In a patient receiving crizotinib (250 mg orally twice daily) who develops fever, how should the fever be evaluated and managed?

Management of Crizotinib-Induced Fever

In a patient receiving crizotinib who develops fever, immediately initiate a standard neutropenic fever workup with blood cultures, chest imaging, and empiric broad-spectrum antibiotics if neutropenic or clinically unstable, while simultaneously evaluating for drug-related pneumonitis—the most serious crizotinib-specific complication that requires urgent chest CT and potential drug discontinuation.

Initial Assessment Framework

When fever develops in a patient on crizotinib (250 mg twice daily), you must distinguish between three primary etiologies:

1. Infection-Related Fever (Most Common)

• Neutropenic fever: Temperature ≥38.3°C or ≥38.0°C for >1 hour with absolute neutrophil count <500/μL 1
• Non-neutropenic infection: Standard infectious workup applies
• Crizotinib itself does not significantly increase infection risk when used as monotherapy 2

2. Drug-Related Pneumonitis (Most Serious)

• Occurs in approximately 2.14% of patients receiving ALK inhibitors (1.33% high-grade) 3
• Presents with fever, dyspnea, cough, and new pulmonary infiltrates
• This is the critical crizotinib-specific complication requiring immediate recognition

3. Drug Fever (Diagnosis of Exclusion)

• Typically occurs 7-10 days after drug initiation 4
• Resolves within 48-72 hours of drug discontinuation
• Consider only after excluding infection and pneumonitis

Immediate Diagnostic Workup

Mandatory Initial Tests:

• Blood cultures (at least 2 sets from different sites; if central line present, draw simultaneously from catheter and periphery) 5
• Complete blood count with differential (assess for neutropenia)
• Chest radiograph 5
• Comprehensive metabolic panel (liver function, renal function)
• Oxygen saturation monitoring

Proceed to Chest CT if:

• Abnormal chest X-ray
• Respiratory symptoms (dyspnea, cough, hypoxia)
• Fever persists >48-72 hours without identified source
• Clinical suspicion for pneumonitis

CT patterns in crizotinib pneumonitis: organizing pneumonia (most common) or diffuse alveolar damage 3

Treatment Algorithm

If Neutropenic (ANC <500/μL):

1. Immediate empiric antibiotics (do not delay for culture results):

   • Monotherapy option: Ceftazidime, cefepime, piperacillin-tazobactam, or carbapenem 1
   • Dual therapy option: Antipseudomonal beta-lactam + aminoglycoside (single daily dose)
   • Add vancomycin only if: severe mucositis, catheter-related infection suspected, or hemodynamic instability 1

2. Continue crizotinib unless pneumonitis suspected

3. Reassess at 48-72 hours:

   • If afebrile and clinically stable: continue antibiotics until ANC >500/μL
   • If persistent fever: broaden coverage, consider antifungal therapy (amphotericin B, voriconazole, or caspofungin) after 4-6 days 6

If Non-Neutropenic with Suspected Pneumonitis:

1. Grade 1 (asymptomatic, radiologic changes only):

   • May continue crizotinib with close monitoring 3
   • Educate patient on warning signs
   • Weekly clinical assessment

2. Grade 2 (symptomatic, not interfering with ADLs):

   • Hold crizotinib immediately
   • Consider corticosteroids (prednisone 0.5-1 mg/kg/day)
   • Rule out infection with cultures, consider bronchoscopy
   • Resume crizotinib only after complete resolution

3. Grade 3-4 (severe symptoms, life-threatening):

   • Permanently discontinue crizotinib 3
   • High-dose corticosteroids (methylprednisolone 1-2 mg/kg/day)
   • ICU-level supportive care if needed
   • Broad-spectrum antibiotics until infection excluded

If Non-Neutropenic Without Pneumonitis:

1. Standard fever workup:

   • Blood cultures, urinalysis/culture
   • Site-specific cultures based on symptoms
   • Imaging as indicated (abdominal CT/ultrasound if abdominal symptoms) 5

2. Empiric antibiotics if:

   • Hemodynamically unstable
   • Immunocompromised (beyond neutropenia)
   • Clear infectious source identified

3. If fever persists >5-7 days without identified source:

   • Consider drug fever
   • Trial discontinuation of crizotinib for 48-72 hours
   • If fever resolves, confirms drug fever; if persists, resume crizotinib and investigate further

Critical Monitoring Parameters

• Temperature: Every 4 hours during acute fever
• Oxygen saturation: Continuous if respiratory symptoms
• Neutrophil count: Daily if neutropenic
• Liver enzymes: Crizotinib can cause transaminitis (ALT elevation in 60% of patients) 7
• Clinical status: Daily assessment for new symptoms, particularly respiratory

Common Pitfalls to Avoid

1. Delaying antibiotics in neutropenic fever: This is an oncologic emergency requiring immediate action 8
2. Missing pneumonitis: Always obtain chest imaging; plain films may be falsely reassuring—proceed to CT if clinical suspicion exists
3. Continuing crizotinib during grade ≥2 pneumonitis: This can progress to life-threatening respiratory failure
4. Attributing fever to drug effect prematurely: Drug fever is a diagnosis of exclusion after thorough infectious and pneumonitis workup
5. Inadequate source control: If catheter-related infection suspected, removal may be necessary despite negative cultures 5

Duration of Antibiotic Therapy

• Neutropenic patients: Continue until afebrile for 48 hours AND ANC >500/μL, or minimum 5-7 days if persistently neutropenic 6
• Documented infection: Treat for organism-specific duration
• No source identified, clinically stable: May discontinue after 48 hours afebrile with negative cultures 1

The key distinction with crizotinib is recognizing drug-related pneumonitis early, as this requires immediate drug discontinuation rather than continuation through fever as you might with simple drug fever or managed infection.